RewordedRisk Factors
Some of our products products, and the related sales development, manufacturing and marketing development commercialization activities and manufacturing processes are subject to extensive and rigorous regulation by the FDA pursuant to the Federal Food, Drug, and Cosmetic Act (the “FDCA”), and by comparable agencies in foreign countries, and by or other regulatory agencies and governing bodies. bodies in the U.S. and around the world.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
All In the EU, medical devices placed on the market in must comply with the EU must meet Medical Devices Regulation, including the general safety and performance requirements laid down in Annex I to the EU Medical Devices Regulation, including the requirement which require that a medical device must be designed and manufactured in such a way that, during normal conditions of use, it is suitable for its intended purpose.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, we may be subject to, among others, the requirements of the EU Corporate Sustainability Reporting Directive, other EU directives, EU and EU member state regulations, various disclosure requirements (such as information on greenhouse gas emissions, climate risks, use of offsets, and emissions reduction claims) and/or from the State of California as well as the SEC’s stayed rule on climate related disclosures, if put in place. California, pending ongoing litigation.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
There are currently different regulations in place in For example, Great Britain currently has a different regulatory framework for our products as compared to both Northern Ireland and the EU.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
However, one of the key topics in the MHRA’s recent consultation was to obtain feedback on whether MHRA intends to remove the requirement for a medical device and its labeling (i.e. packaging and instructions for use) in Great Britain to bear a physical UKCA mark.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Most countries outside of the U.S. require that product approvals be renewed or recertified on a regular basis, generally every four to five years. years, in order for us to continue selling our products in those countries.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
The continuing efforts of governments, insurance companies and other payors of healthcare costs to contain or reduce those costs could lead to patients being unable to obtain approval for payment from these third-party payors for procedures in which our products are used.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
We have invested, and continue to invest, human and technology resources in our data compliance efforts that may be time-intensive and costly.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
•advancing a people first culture that promotes a growth mindset, cohesive and engaged teams, and continuous employee development to enable long‑term organizational excellence.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
On November 12, 2025 we issued 12,650,000 of our 6.50% tangible equity units (the “Units”) at a public offering price of $50.00 per Unit, for an aggregate offering of $632.5 million. We received proceeds of $613.1 million after the deduction of the underwriters fees and other issuance costs. Each Unit is comprised of a prepaid stock purchase contract and a senior amortizing note. Each amortizing note has a principal amount of $8.74 and bears interest at a rate of 6.30% per annum, with a final installment date of November 1, 2028 (“Amortizing Note”).
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
Unless settled early in accordance with the terms of the instruments, and subject to postponement in certain limited circumstances, each prepaid stock purchase contract will automatically settle on November 1, 2028 (the mandatory settlement date) for a number of shares of the Company’s common stock based on the arithmetic average of the volume weighted average price (“VWAPs”) of the Company’s common stock on each of the 20 consecutive trading days beginning on, and including, the 21st scheduled trading day immediately preceding November 1, 2028 ("Applicable Market Value") with reference to the following settlement rates:
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
Applicable Market Value Common Stock Issued Equal to or greater than $134.0842 0.3729 shares (minimum settlement rate) Less than $134.0842 but greater than $107.26 $50 divided by applicable market value Less than or equal to $107.26 0.4662 shares (maximum settlement rate)
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
The purchase contracts are mandatorily convertible into a minimum of 4.7 million shares or a maximum of 5.9 million shares of our common stock on the mandatory settlement date (unless redeemed by us or settled earlier at the unit holder's option). The 4.7 million minimum shares are included in the calculation of basic weighted average shares outstanding.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
The number of shares included in diluted weighted average shares outstanding related to these stock purchase contracts can vary each period, and is determined based on the Applicable Market Value in that reporting period, based on the above settlement rates. If the Applicable Market Value a reporting period is less than $134.0842 but greater than $107.26, then the number of shares included in diluted weighted average shares outstanding will be based on the weighted-average price per share of common stock over the twenty consecutive trading day period immediately preceding the balance sheet date, or November 1, 2028, for settlement of the stock purchase contracts.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
On June 27, 2025, we entered into the Fourth Amended and Restated Credit Agreement. The Fourth Amended and Restated Credit Agreement amends and restates, in its entirety, the Third Amended and Restated Credit Agreement dated as of December 31, 2019 (the “Third Agreement”). The Fourth Amended and Restated Credit Agreement provides for an aggregate credit facility of approximately $1.0 billion, comprised of a €65.3 million euro-denominated 5-year term loan facility (the “Euro Term Loans”), a $75.0 million U.S. dollar denominated 5-year term loan facility (the “U.S. Term Loans”), and an $850.0 million 5-year revolving credit facility (the “Revolving Facility”, and together with the Euro Term Loans and the U.S. Term Loans, collectively, the “Senior Credit Facilities”). The Senior Credit Facilities mature in June 2030 and include an uncommitted “accordion” feature pursuant to which the commitments thereunder may be increased by an additional $350.0 million in aggregate, subject to the satisfaction of certain customary conditions.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
On April 8, 2025, we acquired 100% of the outstanding stock of Keonn Technologies, S.L. (“Keonn”), a Barcelona, Spain-based leader in Radio-Frequency Identification (“RFID”) solutions for a purchase price of €64.8 million ($71.0 million), net of cash acquired, including €4.1 million ($4.5 million) estimated fair value of contingent consideration and €2.0 million ($2.2 million) related to a purchase price holdback. The purchase includes up to €20.0 million ($21.9 million) in contingent consideration payable upon the achievement of certain revenue targets through December 2027. In addition, we have granted equity totaling €9.0 million ($9.9 million) to Keonn employees. Keonn is included in the Medical Solutions reportable segment.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
Information pertaining to fiscal year 2023 results of operations, including a year-over-year comparison with fiscal year 2024, was included in our Annual Report on Form 10-K for the year ended December 31, 2024 under Part II, Item 7, “Management’s Discussion and Analysis of Financial Position and Results of Operations,” which was filed with the SEC on February 25, 2025.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
2025 2024 Gross profit: Automation Enabling Technologies $ 239,506 $ 234,975 Medical Solutions 199,701 189,957 Unallocated (3,923) (3,387) Total $ 435,284 $ 421,545 Gross profit margin: Automation Enabling Technologies 47.8% 47.9% Medical Solutions 41.6% 41.4% Total 44.4% 44.4%
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
% Change 2025 2024 2025 vs. 2024 Research and development and engineering $ 95,484 $ 95,515 0.0% Selling, general and administrative 195,659 175,943 11.2% Amortization of purchased intangible assets 27,477 25,794 6.5% Restructuring, acquisition and related costs 22,652 13,709 65.2% Total $ 341,272 $ 310,961 9.7%
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
On July 4, 2025, the U.S. enacted H.R.1 - One Big Beautiful Bill Act (the “Act”). The Act contains numerous income tax provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act and modifications to the international tax framework. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. We have evaluated the implications of the Act on our consolidated financial statements and related disclosures and have included the impact of items affecting our income tax expense for the twelve months ended December 31, 2025.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RemovedMD&A
•attracting, retaining, and developing world-class talented and motivated employees.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
On January 2, 2024, we completed the acquisition of Motion Solutions Parent Corp. (“Motion Solutions”), an Irvine, California based provider of highly engineered integrated solutions, specializing in proprietary precision motion and advanced motion control solutions, for a total purchase price of $192.0 million in cash, net of working capital adjustments. The acquisition was financed with borrowings under our revolving credit facility. The addition of Motion Solutions enhances our product portfolio and further expands our presence in attractive medical and precision medicine applications. The Motion Solutions acquisition is included in our Medical Solutions reportable segment.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
During the fourth quarter of 2024, we updated our organizational structure and re-aligned our financial reporting structure under two reportable segments: Automation Enabling Technologies and Medical Solutions. Prior to the reorganization, our historical reportable segments were: Precision Medicine and Manufacturing, Robotics and Automation, and Medical Solutions. Prior period segment financial information has been recast to align with the new reportable segments.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
shortages. However, uncertainty remains about overall macroeconomic conditions due to geopolitical tensions and possible changes in trade policies.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
On March 27, 2020, we entered into an amendment (the “First Amendment”) to the Credit Agreement and exercised a portion of the uncommitted accordion feature. The First Amendment increased the revolving credit facility commitment under the Third Amended and Restated Credit Agreement by $145.0 million, from $350.0 million to $495.0 million, and reset the uncommitted accordion feature to $200.0 million for potential future expansion.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
On June 2, 2020, we entered into an amendment (the “Second Amendment”) to the Credit Agreement. The Second Amendment revised our consolidated leverage ratio definition (as defined in the Third Amended and Restated Credit Agreement) allowing for the
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
use of up to $25 million unrestricted cash and cash equivalents as a reduction to consolidated funded indebtedness (as defined in the Third Amended and Restated Credit Agreement).
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
On October 5, 2021, we entered into an amendment (the “Fourth Amendment”) to the Credit Agreement to exercise the accordion feature. The Fourth Amendment increased the revolving credit facility commitment under the Third Amended and Restated Credit Agreement by $200.0 million, from $495.0 million to $695.0 million, and reset the uncommitted accordion feature to $200.0 million for potential future expansion.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
On March 10, 2022, the Company entered into an amendment (the “Fifth Amendment”) to the Credit Agreement to extend the maturity date thereof from December 31, 2024 to March 10, 2027, update the pricing grid, replace LIBOR with SOFR as the reference rate for U.S. dollar borrowings, and increase the uncommitted accordion feature from $200.0 million to $350.0 million.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
reporting unit include assets and liabilities which relate to the reporting unit’s operations. Additionally, reporting units that benefit from corporate assets or liabilities are allocated a portion of those corporate assets and liabilities on a proportional basis.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RewordedMD&A
The net increase in cash and cash equivalents is primarily attributable to $614.4 million of proceeds from the issuance of tangible equity units, net of issuance costs paid, $82.8 million of borrowings under our Senior Credit Facilities, and cash provided by operating activities of $158.5 $64.1 million, and $198.0 million of borrowings under our revolving credit agreement, partially offset by $191.2 $365.7 million of debt repayments, $64.3 million of cash consideration for our 2025 acquisition, $39.3 million related to the 2024 acquisition, $131.1 million repurchase of debt repayments, $17.2 common shares, $15.6 million of capital expenditures, and $9.7 $7.8 million of payroll withholding tax payments related to net share settlement upon vesting of share-based compensation awards.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by financing activities was $56.9 $276.3 million in 2024, 2025, was primarily due to driven by proceeds from the issuance of tangible equity units, net of issuance costs, of $614.4 million, and borrowings under the credit facilities of $198.0 $82.8 million, partially offset by $131.1 $365.7 million of term loan and revolving credit facility repayments and $9.7 repayments, $39.3 million related to the repurchase of common shares, $7.8 million of payroll withholding tax payments related to net share settlement upon vesting of share-based compensation awards. awards, and $4.7 million of payments for debt issuance costs related to our senior credit facilities.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
The borrowings outstanding under the Senior Fourth Amended and Restated Credit Facilities Agreement bear interest at rates based on (a) the Base Rate, as Rate (as defined in the Fourth Amended and Restated Credit Agreement, Agreement) plus a margin ranging between 0.00% to zero and 0.75% per annum, determined by reference to the our consolidated leverage ratio, or (b) the Term SOFR Screen Rate, the Alternative Currency Daily Rate SOFR, SONIA or the Alternative Currency Term Rate, EURIBOR, as defined in the Credit Agreement, applicable, plus a margin ranging between 0.75% 1.00% and 1.75% per annum, determined by reference to our consolidated leverage ratio.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease in operating income was primarily due to an increase in R&D SG&A expenses of $7.7 $6.2 million, an increase in amortization expense of $7.1 million as a result of our 2024 acquisition, an increase in restructuring, acquisition and related costs of $5.6 $5.5 million, an increase in amortization expenses of $3.1 million as a result of our 2025 acquisition, and an increase in SG&A R&D expenses of $4.6 $1.2 million, partially offset by an increase in gross profit of $19.2 $9.7 million.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Medical Solutions Automation Enabling Technologies segment revenue in 2024 2025 increased $76.2 by $10.2 million, or 19.9%, 2.1%, versus 2023, 2024, primarily due to a $30.3 million increase in revenue from our 2024 acquisition, robotics and an increase in sales from our advanced surgery automation products, partially offset by a decrease $20.0 million decline in revenue from our precision medicine manufacturing products.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
This increase was primarily due to revenue from our 2024 acquisition, 2025 acquisition and an increase in revenue in the Automation Enabling Technologies segment, partially offset by a decrease in demand revenue in the advanced industrial and medical end markets. Medical Solutions segment excluding the impact of our 2025 acquisition.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease increase in operating income was primarily due to a decrease an increase in gross profit of $10.2 $4.5 million, and an increase a decrease in restructuring, acquisition and related costs of $6.8 $1.8 million, partially offset by a decrease in amortization expense of $4.7 $1.4 million, and a decrease in R&D expenses of $2.4 $1.2 million, and a decrease partially offset by an increase in SG&A expenses of $0.7 $0.9 million.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Medical Solutions segment revenue in 2024 2025 increased $76.2 $21.1 million, or 19.9%, 4.6%, versus 2023, 2024, primarily due to revenue from our 2024 acquisition, and an driven by a $33.7 million increase in sales revenue from our advanced surgery products, partially offset by a decrease $12.6 million decline in revenue from our precision medicine products.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
In the event Likewise, should we determine that we are will not be able to realize all or part of our net deferred tax assets in the future in excess of their net recorded amounts, future, an adjustment to the valuation allowance for the deferred tax assets would will be recorded and would increase will reduce our net income in the period in which such determination is made.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
The increase decrease in net interest expense was primarily due to an increase in the weighted average interest rate, partially offset by a decrease in average debt levels under our senior credit facilities. and a decrease in the weighted average interest rate.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
We recorded a tax provision of $15.8 million in 2025, compared to a tax provision of $15.0 million in 2024, compared to a tax provision of $10.9 million in 2023. 2024.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Amortization of purchased intangible assets, excluding the amortization of developed technologies that is included in cost of revenue, was $27.5 million, or 2.8% of revenue, in 2025, versus $25.8 million, or 2.7% of revenue, in 2024, versus $20.4 million, or 2.3% of revenue, in 2023. 2024.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new